The Foreign Corrupt Practices Act: Risk-Management and Compliance Strategies For High-Tech Companies
October 16, 2009
Just past its 30th birthday, the Foreign Corrupt Practices Act of 1977 (the FCPA or the Act) today poses the greatest liability risks ever for U.S. firms and other covered entities pursuing business opportunities abroad. Chiefly, this risk arises due to the increased risk of prosecution by the U.S. government, the government’s increased appetite for large fines, and an increased risk of multiple prosecutions due to other countries having adopted FCPA-equivalent laws.
These changes are ones of emphasis and enforcement rather than a wholesale change in how the FCPA operates. The Act has changed little in its basic parameters over the years. Congress unanimously passed the statute in 1977 following an SEC report disclosing that more than 400 U.S. companies, including 117 of the Fortune 500 companies, made “questionable payments” to foreign officials. The FCPA, as enacted, criminalized the making of “corrupt” payments to foreign government and political officials and adopted rigorous recordkeeping requirements for public companies and their overseas subsidiaries.
Author(s)
Related Insights
February 10, 2026
Health Care Law Today
PBM Reform Cheat Sheet: Chart Comparing the Recent Rules for Group Plans
Key Takeaways: Within a one-week period, there were two actions at the federal level to increase pharmacy benefits manager (PBM)…
February 10, 2026
Foley Viewpoints
PBM Reform Cheat Sheet: Chart Comparing the Recent Rules for Group Plans
Key Takeaways: Within a one-week period, there were two actions at the federal level to increase pharmacy benefits manager (PBM)…
March 26, 2026
Events
Exploring the Subtleties and Safe Zones of Off-Label Communications — Part 2
Foley partner Kyle Faget, co-chair of the Medical Devices & Equipment Area of Focus within the firm’s Health Care & Life Sciences Sector, is speaking on the panel “Exploring the Subtleties and Safe Zones of Off-Label Communications — Part 2” during the American Conference Institute’s FDA Boot Camp program on Thursday, March 26.